Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) have earned an average rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $110.6154.

Several analysts have commented on the stock. Wells Fargo & Company reissued an “overweight” rating and issued a $114.00 target price (up from $106.00) on shares of Soleno Therapeutics in a research report on Tuesday, January 20th. HC Wainwright reiterated a “buy” rating and issued a $120.00 price objective (up from $110.00) on shares of Soleno Therapeutics in a report on Tuesday, January 20th. Zacks Research downgraded shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Finally, Wall Street Zen raised Soleno Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th.

Soleno Therapeutics Stock Up 0.3%

SLNO opened at $38.61 on Thursday. The company has a market capitalization of $2.07 billion, a PE ratio of -20.98 and a beta of -3.16. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88. Soleno Therapeutics has a fifty-two week low of $36.67 and a fifty-two week high of $90.32. The business has a 50-day moving average of $44.04 and a 200-day moving average of $55.43.

Hedge Funds Weigh In On Soleno Therapeutics

A number of institutional investors have recently modified their holdings of SLNO. Raymond James Financial Inc. bought a new stake in shares of Soleno Therapeutics during the 2nd quarter worth $25,000. Danske Bank A S acquired a new position in Soleno Therapeutics during the 3rd quarter worth $27,000. Global Retirement Partners LLC lifted its position in Soleno Therapeutics by 519.0% during the 4th quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock worth $29,000 after acquiring an additional 519 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in Soleno Therapeutics during the third quarter valued at about $37,000. Finally, Nisa Investment Advisors LLC boosted its holdings in Soleno Therapeutics by 287.8% during the second quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock valued at $45,000 after acquiring an additional 400 shares during the period. Institutional investors own 97.42% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.